The Influence of Cell Cycle Regulation on Chemotherapy

Application of Nano-Drug Delivery System Based on Cascade Technology in Cancer Treatment

(2021) Ying Sun et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Marine Polysaccharides as a Versatile Biomass for the Construction of Nano Drug Delivery Systems

(2021) Ying Sun et al.   Marine Drugs

PAMAM-Functionalized Cellulose Nanocrystals with Needle-Like Morphology for Effective Cancer Treatment

(2021) Yanzhen Sun et al.   Nanomaterials

Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity

(2020) Le-le Zhang et al.   ACTA PHARMACOLOGICA SINICA

A comprehensive review on microbial l ‐asparaginase: Bioprocessing, characterization, and industrial applications

(2020) Subhash Chand et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

PARP and PARG inhibitors in cancer treatment

(2020) Dea Slade   GENES & DEVELOPMENT

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

(2020) Florence Coussy et al.   Science Translational Medicine

Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age

(2020) Rita Ferreira et al.   Cells

Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells

(2020) Eva Aubets et al.   BIOCHEMICAL PHARMACOLOGY

Radiothérapie avec modulation d’intensité préopératoire des cancers rectaux : intérêt et application

(2020) V. Randrian et al.   Cancer Radiotherapie

3,3′,5,5′-tetramethoxybiphenyl-4,4′diol induces cell cycle arrest in G2/M phase and apoptosis in human non-small cell lung cancer A549 cells

(2020) Virginia Marcia Concato et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Dissenting degradation: Deubiquitinases in cell cycle and cancer

(2020) Thomas Bonacci et al.   SEMINARS IN CANCER BIOLOGY

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

(2020) Fei Xu et al.   Cell and Bioscience

Modulating effect of Coronarin D in 5-fluorouracil resistance human oral cancer cell lines induced apoptosis and cell cycle arrest through JNK1/2 signaling pathway

(2020) Ming-Yu Hsieh et al.   BIOMEDICINE & PHARMACOTHERAPY

Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action

(2020) Aleen Khoury et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Effect and mechanism of PI3K/AKT/mTOR signaling pathway in the apoptosis of GC-1 cells induced by nickel nanoparticles

(2020) Yongya Wu et al.   CHEMOSPHERE

Synergistic Cytotoxic Effect of Busulfan and the PARP inhibitor Veliparib in Myeloproliferative Neoplasms

(2019) Pritesh R. Patel et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cellular and molecular mechanisms of curcumin in prevention and treatment of disease

(2019) Sita Sharan Patel et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Boolean model of growth signaling, cell cycle and apoptosis predicts the molecular mechanism of aberrant cell cycle progression driven by hyperactive PI3K

(2019) Herbert Sizek et al.   PLoS Computational Biology

A New Electrochemical Sensor for Direct Detection of Purine Antimetabolites and DNA Degradation

(2019) Liliya K. Shpigun et al.   Journal of Analytical Methods in Chemistry

Anticancer polymers designed for killing dormant prostate cancer cells

(2019) Haruko Takahashi et al.   Scientific Reports

DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents

(2019) Maria Raimondi et al.   MOLECULES

Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death

(2019) Wei-Hsun Hsu et al.   Journal of Thoracic Oncology

Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions

(2019) Haroon Khan et al.   BIOTECHNOLOGY ADVANCES

Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells

(2019) Bethtrice Elliott et al.   CANCER LETTERS

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer.

(2019) Eve Combes et al.   CANCER RESEARCH

JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells

(2019) Lei Duan et al.   ONCOGENE

Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species

(2019) Xiaoyu Zhang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Toxic effects and involved molecular pathways of nanoparticles on cells and subcellular organelles

(2019) Na Liu et al.   JOURNAL OF APPLIED TOXICOLOGY

Probes and drugs that interfere with protein translation via targeting to the RNAs or RNA-protein interactions

(2019) Miss Sui-Qi Cheng et al.   METHODS

ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation

(2019) Luciana Rodrigues Gomes et al.   Cell Death & Disease

Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

(2019) Gesuino Angius et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.

(2019) Triparna Sen et al.   Journal of Thoracic Oncology

Withaferin A inhibits expression of ataxia telangiectasia and Rad3‐related kinase and enhances sensitivity of human breast cancer cells to cisplatin

(2019) Eun‐Ryeong Hahm et al.   MOLECULAR CARCINOGENESIS

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

(2019) Mandeep Atwal et al.   MOLECULAR PHARMACOLOGY

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

(2019) Robert L. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel DNA repair inhibitor, diallyl disulfide (DADS), impairs DNA resection during DNA double-strand break repair by reducing Sae2 and Exo1 levels

(2019) Chen-Hsin Kuo et al.   DNA REPAIR

Silver nanoparticles induce cell death of colon cancer cells through impairing cytoskeleton and membrane nanostructure

(2019) Hefang Xiao et al.   MICRON

An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks

(2019) Tshering D. Lama-Sherpa et al.   MOLECULAR CANCER RESEARCH

Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage

(2019) Nicholas J. H. Warren et al.   ONCOGENE

Curcumin and Cancer

(2019) Giordano et al.   Nutrients

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements

(2019) Vaishali Aggarwal et al.   Biomolecules

Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma

(2019) Meijuan Geng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase I Consortium Report (ADVL1312)

(2019) Kristina A. Cole et al.   CLINICAL CANCER RESEARCH

Dihydroartemisinin inhibits endothelial cell tube formation by suppression of the STAT3 signaling pathway

(2019) Peng Gao et al.   LIFE SCIENCES

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

(2019) Alice Bradbury et al.   PHARMACOLOGY & THERAPEUTICS

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

(2019) Jun-Hai Tang et al.   Cancer Communications

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

(2018) A Italiano et al.   ANNALS OF ONCOLOGY

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others

(2018) Ying Chen et al.   BIOMEDICINE & PHARMACOTHERAPY

The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer

(2018) Alice Lallo et al.   CLINICAL CANCER RESEARCH

PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials

(2018) Dalia Kamel et al.   CURRENT DRUG TARGETS

Cytotoxicity of Silver Nanoparticles Against Bacteria and Tumor Cells

(2018) Tianyuan Shi et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

(2018) Liwei Lang et al.   Journal of Hematology & Oncology

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

(2018) Shaocong Wu et al.   Molecular Cancer

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives

(2018) Gantumur Battogtokh et al.   Acta Pharmaceutica Sinica B

Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death

(2018) Joshua M. Marcus et al.   CELL CYCLE

DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride

(2018) Li-Min Liu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation

(2018) Zixing Liu et al.   ONCOGENE

A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity

(2018) Maria Yusenko et al.   Scientific Reports

Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance

(2018) Monish Ram Makena et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

Targeting the centrosome and polo-like kinase 4 in osteosarcoma

(2018) Fergal C Kelleher et al.   CARCINOGENESIS

Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

(2018) Caitlin D Lowery et al.   CLINICAL CANCER RESEARCH

Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target

(2018) Thomas Grellety et al.   CLINICAL CANCER RESEARCH

The role of cellular reactive oxygen species in cancer chemotherapy

(2018) Haotian Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

State-of-the-art strategies for targeting the DNA damage response in cancer

(2018) Patrick G. Pilié et al.   Nature Reviews Clinical Oncology

ROS and the DNA damage response in cancer

(2018) Upadhyayula Sai Srinivas et al.   Redox Biology

The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells

(2017) Yun Cai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safe approaches for camptothecin delivery: Structural analogues and nanomedicines

(2017) Pablo Botella et al.   JOURNAL OF CONTROLLED RELEASE

Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species

(2017) Ping’an Ma et al.   NANO LETTERS

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells

(2017) Karine Flem-Karlsen et al.   Pigment Cell & Melanoma Research

ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

(2017) Cyril Ronco et al.   MedChemComm

Induction of oxidative stress by anticancer drugs in the presence and absence of cells

(2017) Chikako Yokoyama et al.   Oncology Letters

Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3

(2016) Cheng-Shi He et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic

(2016) Weilan Ye   DEVELOPMENTAL CELL

Resokaempferol-mediated anti-inflammatory effects on activated macrophages via the inhibition of JAK2/STAT3, NF-κB and JNK/p38 MAPK signaling pathways

(2016) Qian Yu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Two new phenolic compounds and antitumor activities of asparinin A from Asparagus officinalis

(2016) Xue-Mei Li et al.   JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH

Syk expression in non-small-cell lung cancer and its relation with angiogenesis

(2016) Cong Bo et al.   Journal of Cancer Research and Therapeutics

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

(2016) David Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Interference of Selected Cytotoxic Alkaloids with the Cytoskeleton: An Insight into Their Modes of Action

(2016) Xiaojuan Wang et al.   MOLECULES

Activation of the ATR kinase by the RPA-binding protein ETAA1

(2016) Peter Haahr et al.   NATURE CELL BIOLOGY

Topoisomerase I and II Inhibitors: A Patent Review

(2016) Arshdeep Singh et al.   Recent Patents on Anti-Cancer Drug Discovery

Effects of L.   paracasei subp. paracasei X12 on cell cycle of colon cancer HT-29 cells and regulation of mTOR signalling pathway

(2016) Lei Huang et al.   Journal of Functional Foods

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Generated 3D-Common Feature Hypotheses Using the HipHop Method For Developing New Topoisomerase I Inhibitors

(2015) Sanaz Ataei et al.   ARCHIV DER PHARMAZIE

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321

(2015) Yujie Zhao et al.   Journal of Thoracic Oncology

Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines

(2015) S. Junk et al.   KLINISCHE PADIATRIE

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells

(2015) Wei Zhang et al.   OncoTargets and Therapy

Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death

(2015) Joungyoun Noh et al.   Nature Communications

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

(2015) Xiu-Xiu Chen et al.   Oncotarget

Transcriptional control of stem cell fate by E2Fs and pocket proteins

(2015) Lisa M. Julian et al.   Frontiers in Genetics

Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis

(2014) E. Rodriguez-Diez et al.   BLOOD

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide

(2014) Lucio Tentori et al.   BMC CANCER

Signaling pathway switch in breast cancer

(2013) Arnaud Guille et al.   Cancer Cell International

Tumour selective targeting of cell cycle kinases for cancer treatment

(2013) Marieke Aarts et al.   CURRENT OPINION IN PHARMACOLOGY

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

Neo-endocrinochemotherapy: A novel approach for enhancing chemotherapeutic efficacy in clinic?

(2013) Jianbo Huang et al.   MEDICAL HYPOTHESES

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cell Death from Antibiotics Without the Involvement of Reactive Oxygen Species

(2013) Y. Liu et al.   SCIENCE

Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma

(2013) XIN ZHAO et al.   Oncology Letters

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Mechanisms of replication fork protection: a safeguard for genome stability

(2012) Alessia Errico et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients

(2012) Gun Min Kim et al.   Journal of Thoracic Oncology

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Bilal Piperdi et al.   Journal of Thoracic Oncology

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

(2012) H.-J. Nam et al.   MOLECULAR CANCER THERAPEUTICS

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

Glutamine Treatment Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced Colitis

(2012) Irene Crespo et al.   PLoS One

In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy

(2011) Sabrina Riedl et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy

(2011) F. Wei et al.   CURRENT MEDICINAL CHEMISTRY

B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation

(2011) H. Liu et al.   MOLECULAR CANCER THERAPEUTICS

All tangled up: how cells direct, manage and exploit topoisomerase function

(2011) Seychelle M. Vos et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Dynamics of Uracil and 5-Fluorouracil in DNA

(2010) Jared B. Parker et al.   BIOCHEMISTRY

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

(2010) Neta Erez et al.   CANCER CELL

Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters

(2010) C. J. Morrow et al.   CANCER RESEARCH

Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study

(2010) Raphaël Beck et al.   INVESTIGATIONAL NEW DRUGS

Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels

(2010) Kaspar Burger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe

(2009) Oliver Riesterer et al.   INVESTIGATIONAL NEW DRUGS

A novel combination chemotherapy integrating with intratumoral chemotherapy

(2009) Lichun Yang et al.   MEDICAL HYPOTHESES

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

RNA interference-mediated silencing of thepolo-like kinase 1gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells

(2008) C. Yu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Global control of cell-cycle transcription by coupled CDK and network oscillators

(2008) David A. Orlando et al.   NATURE

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE